SCHEMBL2010215

SCHEMBL2010215

c1cn2cnc3occc3c2n1

nearest known ligand 0.34

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
NUDT1 P36639 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12677712 0.71 USP7 (0.31)
SCHEMBL29485626 0.67 KDM4E (0.45) NUDT1
SCHEMBL1370906 0.67 KDM4E (0.45) NUDT1
SCHEMBL24659084 0.66 NUDT1 (0.35) NUDT1
SCHEMBL14216744 0.65 CDK5 (0.32)
SCHEMBL17732805 0.62 IKBKB (0.41)
SCHEMBL20388085 0.62 FADS1 (0.35) NUDT1
SCHEMBL10447630 0.61 NUDT1 (0.34) NUDT1
SCHEMBL22554158 0.60 PRKCI (0.41)
SCHEMBL22270836 0.60 KCNA3 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110150961-A1 ANTI-INFECTIVE CATHETERS ANGIOTECH INTERNATIONAL AG (CH) 2011-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110150961-A1 ANTI-INFECTIVE CATHETERS NACA, PUF60, POLR1C NUDT1 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.